PLOS ONE

CORRECTION

Correction: Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer

Huifang Hao, Yutaka Maeda, Takuya Fukazawa, Tomoki Yamatsuji, Munenori Takaoka, Xiao-Hong Bao, Junji Matsuoka, Tatsuo Okui, Tsuyoshi Shimo, Nagio Takigawa, Yasuko Tomono, Motowo Nakajima, Iris M. Fink-Baldauf, Sandra Nelson, William Seibel, Ruben Papoian, Jeffrey A. Whitsett, Yoshio Naomoto

In Fig 5, the beta-actin is incorrect in panel B. Please see the correct Fig 5 here.

Citation: Hao H, Maeda Y, Fukazawa T, Yamatsuji T, Takaoka M, Bao X-H, et al. (2024) Correction: Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer. PLoS ONE 19(7): e0307052. https://doi.org/10.1371/journal.pone.0307052

Published: July 9, 2024



Fig 5. iMDK inhibited the PI3K/AKT pathway and influenced the apoptosis pathway. A. Dose-dependently, phosphorylation of PI3K and AKT and the expression of survivin and XIAP, anti-apoptotic factors, were decreased while the expression of BAD, a pro-apoptotic factor, was increased 48 hours after treatment with iMDK. Shown is immunoblot performed as described in Methods. **B.** Time-dependently, phosphorylation of PI3K and AKT and the expression of survivin and XIAP were decreased while the expression of BAD was increased by treatment with iMDK at a concentration of 50 nM. Immunoblot was performed as described in Methods.

https://doi.org/10.1371/journal.pone.0307052.g001

Reference

1. Hao H, Maeda Y, Fukazawa T, Yamatsuji T, Takaoka M, Bao X-H, et al. (2013) Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer. PLoS ONE 8(8): e71093. https://doi.org/10.1371/journal.pone.0071093 PMID: 23976985